source
- Former FDA officials and pharma groups weigh in as Supreme Court considers mifepristone regulationThe Supreme Court is expected to act on a case involving the abortion pill mifepristone after a pause on a federal appeals court order that halted mail‑order distribution. The decision could resha…
- Pimicotinib shows 76% response rate and functional benefits in TGCT phase 3 trialDr. Randall discussed results from the phase 3 MANEUVER trial of the CSF-1 receptor inhibitor pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The data were presented at the 2025…